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Fig. 1. Various RARA partner genes in acute promyelocytic leukemias.
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Letter to the Editor
Molecular methods for genomic 
analyses of variant PML-RARA 
or other RARA-related chromo-
somal translocations in acute 
promyelocytic leukemia
TO THE EDITOR: We read an  interestin g paper by Palta 
et al. in a recent issue of the Korean Journal of Hematology 
titled, “ZBTB16-RARA variant of acute promyelocytic leuke-
mia with tuberculosis: a case report and review of literature” 
[1]. We would like to add some comments to their article 
and suggest additional molecular methods to confirm variant 
translocations in acute promyelocytic leukemia (APL).
Apart from its characteristic morphology, APL is strongly 
correlated with presence of the PML-RARA fusion gene 
due to a t(15;17) translocation. Patients displaying cryptic 
PML-RARA gene rearrangements or other translocations 
involving RARA are very rare. Since RARA generates chi-
meric fusion genes with various partners such as ZBTB16 
at 11q23, NUMA1 at 11q13, NPM1 at 5q35, FIP1L1 at 4q12, 
and STAT5b at 17q11.2 (Fig. 1), confirmatory molecular 
methods to detect gene rearrangements are necessary when 
unique or unusual chromosomal translocations are found 
in APL cases. Palta et al. reported a case of APL accompanied 
by tuberculosis where cytogenetic study showed a variant 
chromosomal translocation, t(11;17)(q23;q21). First, al-
though they describe this case as APL with t(11;17)(q23;q21) 
through bone marrow (BM), immunophenotyping, and cy-
togenetic studies, we noted an absence of results based on 
molecular methods. To demonstrate the existence of the 
ZBTB16-RARA fusion gene, a single specific reverse tran-
scriptase-polymerase chain reaction (RT-PCR) with a specif-
ic primer to detect the gene rearrangement or multiplex 
RT-PCR (e.g. HemaVision) to detect ZBTB16-RARA could 
have provided an accurate molecular diagnostic result. 
Second, the authors’ reference to a paper by Kang et al. 
was puzzling despite the fact that it was cited as a similar 
case with chromosomal translocations at a similar location, 
in cases of AML with chromosomal translocation t(11;17) 
[2]. In the first case, cytogenetic analysis from BM aspirate 
showed t(11;17)(q23;q21) in 18 out of 20 cells while the 
MLL probe in fluorescence in situ hybridization (FISH) 
showed split-out signals in 98.5% of interphase cells. The 
second case also showed t(11;17)(q23;q25) in the chromo-
some study while the FISH assay showed split-out signals 
in 79% of interphase cells. However, normal fluorescence 
patterns were found in 200 cells in additional FISH assays 
when a dual-color single-fusion PML-RARA probe was used 
for both cases, which led to the conclusion that the MLL 
gene was involved in the 11q23 breakpoint and RARA was 
not involved in the 17q breakpoint. Hence, the authors’ Korean J Hematol 2012;47:307-8.
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citation of this study to explain the ZBTB16-RARA fusion 
gene appears inadequate, and a molecular study could un-
ambiguously identify the involvement of ZBTB16 at 11q23 
in their case.
We suggest the authors conduct RT-PCR analysis of the 
ZBTB16-RARA fusion gene if any remnant RNA or cDNA 
samples from their APL patient are available. However, 
if only genomic DNA is available, analyzing the genomic 
breakpoints by multiplex long distance-polymerase chain 
reaction (LD-PCR) would be helpful. LD-PCR or long dis-
tance inverse (LDI)-PCR can identify known or unknown 
partner genes, monitor minimal residual disease (MRD), 
and identify multi-way chromosomal translocations such 
as three-way or four-way translocations [3]. We have re-
cently used LD-PCR to confirm APL cases showing unusual 
karyotypes or discrepant results between conventional cyto-
genetics and molecular studies. More precisely, we identified 
a novel PML-ADAMTS17-RARA rearrangement and con-
firmed the genomic fusion breakpoints of cryptic PML- 
RARA rearrangement in 2 APL patients [3-5].
In conclusion, detection of leukemia-associated fusion 
genes is important due to their direct relevance to diagnosis, 
MRD assessment, and treatment response. Since APL pa-
tients with ZBTB16-RARA are resistant to all-trans-retinoic 
acid (ATRA), molecular methods with higher resolution 
than chromosome studies must be conducted to detect fusion 
genes and facilitate selection of the most appropriate 
treatment. We believe that molecular techniques such as 
FISH , R T -PC R ,  an d L D-P C R  sh o u l d b e u se d in  ad dit io n 
to morphology and cytogenetic studies in APL diagnosis 
and evaluation so that atypical PML-RARA or RARA variant 
gene rearrangements are not missed.
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